Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Blood

Volumn 98, Issue 1, 2001, Pages 210-216

  Davies, Faith E ^a,b,c,d   Raje, Noopur ^a,b,c,d   Hideshima, Teru ^a,b,c,d   Lentzsch, Suzanne ^a,b,c,d   Young, Gloria ^a,b,c,d   Tai, Yu Tzu ^a,b,c,d   Lin, Boris ^a,b,c,d   Podar, Klaus ^a,b,c,d   Gupta, Deepak ^a,b,c,d   Chauhan, Dharminder ^a,b,c,d   Treon, Steven P ^a,b,c,d   Richardson, Paul G ^a,b,c,d   Schlossman, Robert L ^a,b,c,d   Morgan, Gareth J ^a,b,c,d   Muller, George W ^a,b,c,d   Stirling, David I ^a,b,c,d   Anderson, Kenneth C ^a,b,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 2; THALIDOMIDE;

ARTICLE; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035412366     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.210     Document Type: Article

References (18)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
2. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cell lines to conventional therapy. Blood. 2000;96:2943-2950.
3. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effects of interleukin-6 against dexamethasone induced apoptosis in multiple myeloma cells. J Biol Chem. 2000;275:27845-27850.
4. Waters MF. Use of thalidomide in leprosy [abstract]. BMJ. 1991;303:470.
5. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1487-1493.
6. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-1058.
7. Sampalo EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
8. + subset. J Exp Med. 1998;187:1885-1892.
9. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380-386.
10. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
11. Raje N, Gong J, Chauhan D, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999;93:1487-1495.
12. Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma derived cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood. 1993;82:3712-3720.
13. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:27-42.
14. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754-765.
15. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. In press.
16. Aparicio A, Gardner A, Tu Y, et al. In-vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998;12:220-229.
17. Shipman CM, Croucher PI, Russell GG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells lines in vitro by inhibiting the melvalonate pathway. Cancer Res. 1998;58:5294-5207.
18. Kunzmann V, Bauer E, Feurle J, Weibinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood. 2000;96:384-392.